NBIX Q3 2026 Revenue Swells 41% to $1.1B
Neurocrine Biosciences reported $1.1 billion total revenue in Q3 2026, driving INGREZZA net product sales above $801 million and raising its full-year 2026 sales guidance to $2.9 - $2.925 billion.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed